Source link : https://www.newshealth.biz/health-news/durvalumab-enhances-survival-in-sclc/
TOPLINE: Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival was 55.9 months for durvalumab vs 33.4 months for placebo. METHODOLOGY: In the ADRIATIC trial, 730 patients with limited-stage SCLC and no disease progression after chemoradiotherapy were randomly assigned to receive […]
Author : News Health
Publish date : 2024-10-08 12:19:15
Copyright for syndicated content belongs to the linked Source.